Corporate News

VISITECT® COVID-19 antigen test performs with the same high accuracy on the Omicron variant

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, has been notified by its technology partner Mologic Ltd (“Mologic”) that data from analysis on clinical samples, as well as in-silico analysis, show that the Mologic Covios® Ag lateral flow test, performs with the same high accuracy on the Omicron variant as it does with existing known variants.

This is the same test that is manufactured and sold for professional use by Omega as the VISITECT® COVID-19 antigen test.

Colin King, CEO, Omega Diagnostics, said: “We are very pleased be in a position to confirm that the VISITECT® COVID19 antigen test is able to equally detect the Omicron variant, as well as other existing variants. We remain encouraged by emerging commercial opportunities for our VISITECT® COVID-19 Antigen test that we expect to be unlocked following relevant approval under CTDA regulations and CE-marking for home-use.”

Contacts:  

Omega Diagnostics Group PLC	www.omegadx.co
Colin King, Chief Executive	via Walbrook PR
Chris Lea, Chief Financial Officer
finnCap Ltd	Tel: 020 7220 0500
Geoff Nash / Edward Whiley (Corporate Finance)
Alice Lane / Charlotte Sutcliffe (ECM)
Walbrook PR Limited
Paul McManus	Mob: 07980 541 893
Lianne Applegarth	Mob: 07584 391 303
Sam Allen	Mob: 07502 558 258

 

About Omega Diagnostics Group PLC 

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health. www.omegadx.com